FDA Alerts
FDA: Don't Take Diamond 3500
The Food and Drug Administration (FDA) is advising consumers not to purchase or use Diamond 3500, a product promoted and sold for sexual enhancement on various websites and in some retail stores.
FDA Warns Against Sex Enhancement Pill
The Food and Drug Administration (FDA) is advising consumers not to purchase or use Eros Power Zone 1900, a product promoted and sold for sexual enhancement on various websites and in some retail stores.
ED Supplement May Pose Health Risk
The Food and Drug Administration (FDA) is advising consumers not to purchase or use Triple MiracleZen Gold 1750 mg, a product promoted and sold for sexual enhancement on various websites and in some retail stores.
Male Enhancement Product May Pose Health Risk
The Food and Drug Administration (FDA) is advising consumers not to purchase or use Xtra Zone 2400, a product promoted and sold for sexual enhancement on various websites and in some retail stores.
FDA Approves Label Changes to Blood Pressure Medicine Olmesartan Medoxomil
The US Food and Drug Administration (FDA) is warning that the blood pressure drug olmesartan medoxomil (marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics) can cause intestinal problems known as sprue-like enteropathy.
FDA: Blood Pressure Medication Warning
The U.S. Food and Drug Administration (FDA) is warning of possible risks when using blood pressure medicines containing aliskiren with other drugs called angiotensin converting enzyme inhibitors ( ACEIs ) and angiotensin receptor blockers ( ARBs ) in patients with diabetes or kidney (renal) impairment.
FDA Drug Safety Communication: Tekturna
The U.S. Food and Drug Administration (FDA) is warning of possible risks when using blood pressure medicines containing aliskiren with other drugs called angiotensin converting enzyme inhibitors ( ACEIs ) and angiotensin receptor blockers ( ARBs ) in patients with diabetes or kidney (renal) impairment.
FDA Drug Safety Communication: Letairis
The U.S. Food and Drug Administration (FDA) is removing the warning related to liver injury from the boxed warning of the Letairis ( ambrisentan ) tablet label.
FDA Drug Safety Communication: Benicar
After reviewing the results of the ROADMAP and ORIENT trials, the FDA has determined that the benefits of Benicar continue to outweigh its potential risks when used for the treatment of patients with high blood pressure according to the drug label. Benicar is not recommended as a treatment to delay or prevent protein in the urine ( microalbuminuria ) in diabetic patients.
Patients should consult their healthcare professional if they have any questions or concerns about taking Benicar .
Daiichi Sankyo , the makers of Benicar , have agreed to work with the FDA to perform additional ...
New Drug to Relieve the Pressure
The U.S. Food and Drug Administration (FDA) today approved Edarbi tablets ( azilsartan medoxomil ) to treat high blood pressure (hypertension) in adults.